Avicenna Therapeutic Tech, Inc. is developing MIST, a plungerless syringe system that replaces 70-year-old injection technology. Instead of a plunger, a magnetic actuator moves a piston inside a vacuum-sealed cartridge. The drug never touches silicone oil, there are no air bubbles, and medicines can be stored for longer with less reliance on refrigerated shipping.
MIST is designed for liquids, thick formulations and gases, including sensitive biologics and mRNA vaccines. One sealed cartridge replaces both the vial and the syringe, so pharma and biotech partners can cut waste, fill-finish costs and cold-chain spend. Founded in 2026, Avicenna plans to earn from cartridge sales, licensing, actuators and co-development partnerships.
Injectables still rely on 70-year-old syringe technology. Short shelf life, silicone oil, leakage and refrigerated shipping all add cost and risk, and an estimated $35 billion or more is lost globally each year to injectable logistics failures. Avicenna’s MIST system is designed to remove those weak points.
Injectables still rely on 70-year-old syringe technology. Short shelf life, silicone oil, leakage and refrigerated shipping all add cost and risk, and an estimated $35 billion or more is lost globally each year to injectable logistics failures. Avicenna’s MIST system is designed to remove those weak points.
Injectables still rely on 70-year-old syringe technology. Short shelf life, silicone oil, leakage and refrigerated shipping all add cost and risk, and an estimated $35 billion or more is lost globally each year to injectable logistics failures. Avicenna’s MIST system is designed to remove those weak points.
“Real progress in healthcare starts with reducing the burden on patients. MIST does that — less waste, less friction, more dignity in self-care.”
The Team
Professor Boris Zubry
CEO
The inventor of MIST, Avicenna’s patented magnetic plungerless injection system. Boris has an engineering and management background spanning pharmaceuticals, cosmetics, packaging and food, including roles at major pharma and packaging companies. He has spent the past decade teaching math, physics, GMP and quality control at several colleges, and holds multiple patent filings.
Dr. Christopher Tirotta
CEO
A physician and anesthesiologist who practiced at Miami Children’s Hospital from 1991 to 2023, where he led the Department of Anesthesia. Christopher has led clinical trials for multiple drug and device companies, holds an MBA, and is board-certified in anesthesiology and pediatric anesthesia. He was appointed CEO of Avicenna in January 2026.
Christopher Meatto
Counsel & Fund Administrator
Managing Partner of HL74, an advisory and legal platform for startups and growth-stage companies. A Harvard Law School graduate, Christopher has more than 20 years of experience advising on corporate strategy, financings, governance and partnerships, and has founded a law firm, a watch company and NYCG.COM.
Join the deal
Join the Healthcare Shares Community
stay connected to the people shaping the future of healthcare.
